Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eric Chang

Plastic and Reconstructive Surgery Florham Park, NJ Medical Doctor

NPI 1831352871 CMS profile 82864

83 Hanover Rd Ste 260, Florham Park, NJ 07932

Open in the dashboard

General payments

$41,498

201 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eric Chang of Florham Park, NJ is reported in the CMS Open Payments database as having received $41,498 across 201 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Plastic and Reconstructive Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,292 30
2024 General $6,932 30
2023 General $9,370 32
2022 General $2,462 32
2021 General $3,136 29
2020 General $2,824 11
2019 General $11,483 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eric Chang
  • Plastic and Reconstructive Surgery median
  • Middle half of Plastic and Reconstructive Surgery
  • National median

In program year 2025, general payments to Eric Chang were reported at $5,292. Among 2,070 Plastic and Reconstructive Surgery profiles paid that year, the median was $442 and the middle half received between $150 and $1,242.

Show as a table
Year Eric Chang Plastic and Reconstructive Surgery median Middle half National median
2019 $11,483 $335 $121–$1,264 $163
2020 $2,824 $162 $57–$417 $114
2021 $3,136 $245 $89–$735 $132
2022 $2,462 $325 $120–$932 $149
2023 $9,370 $343 $129–$999 $160
2024 $6,932 $390 $141–$1,085 $164
2025 $5,292 $442 $150–$1,242 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Musculoskeletal Transplant Foundation Inc. $17,251 59 payments
  2. Aziyo Biologics, Inc. $9,073 16 payments
  3. AxoGen $3,657 21 payments
  4. AbbVie, Inc. $2,965 16 payments
  5. Allergan Inc. $2,326 14 payments
  6. TELA Bio, Inc. $2,213 12 payments
  7. Mentor Worldwide LLC $1,210 26 payments
  8. Sientra, Inc. $1,129 14 payments
  9. Integra LifeSciences Corporation $675 6 payments
  10. RTI Surgical, Inc $298 4 payments
  11. Other $700 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $14,550 26 payments
  2. Consulting Fee $13,487 10 payments
  3. Food and Beverage $13,194 163 payments
  4. Long term medical supply or device loan $245 1 payment
  5. Entertainment $22 1 payment
Products named General payments · program years 2019–2025
  1. SimpliDerm $7,648 12 payments
  2. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastic Surgery $4,715 18 payments
  3. REVOLVE $4,280 16 payments
  4. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastics $4,154 18 payments
  5. AXOGUARD NERVE PROTECTOR $3,482 20 payments
  6. AxoGuard Nerve Connector $3,482 20 payments
  7. STRATTICE RECONSTRUCTIVE TISSUE MATRIX BPS $2,320 9 payments
  8. OviTex 2S $1,652 3 payments
  9. MENTOR MemoryGel Resterilizable Gel Sizer $1,195 25 payments
  10. SIENTRA HIGH STRENGTH COHESIVE SILICONE GEL BREAST IMPLANT $1,129 14 payments
  11. Other $7,739 83 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

25

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$5,135

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

44%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 11 $5,082
Silver Sulfadiazine Generic 14 $54

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 54 billing codes

Paid by Medicare

$130,625

Medicare's payments for the services billed

Medicare patients

52

Average age 70

Services billed

529

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 67%
Cancer 62%
Ischemic heart disease 37%
Diabetes 31%
Depression 27%
Heart failure 25%
Osteoporosis 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

201 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic and Reconstructive Surgery in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record